Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators.

Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.

PMID:
23246022
2.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

Ann Oncol. 2003 Jun;14(6):833-42. Review.

3.

Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?

Perez EA.

Curr Oncol Rep. 2003 Jan;5(1):66-71. Review.

PMID:
12493153
4.

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.

Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, McLeod D, Pritchard K, Provencher L, Verma S.

Lancet Oncol. 2005 Nov;6(11):886-98. Review.

PMID:
16257797
5.

Optimizing adjuvant chemotherapy in early-stage breast cancer.

Perez E, Muss HB.

Oncology (Williston Park). 2005 Dec;19(14):1759-67; discussion 1768, 1772-4, 1777-8. Review.

6.

Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.

Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT.

JAMA Oncol. 2015 Dec;1(9):1311-8. doi: 10.1001/jamaoncol.2015.3062. Review.

PMID:
26402167
7.

[Impact of taxanes in the adjuvant setting of node-negative breast cancers].

Lagha A, Chraiet N, Labidi S, Krimi S, Ayadi M, Gligorov J, Boussen H.

Bull Cancer. 2013 May;100(5):465-71. doi: 10.1684/bdc.2013.1743. Review. French.

PMID:
23613145
8.

Can we abandon anthracyclines for early breast cancer patients?

Henderson IC.

Oncology (Williston Park). 2011 Feb;25(2):115-24, 127. Review.

9.

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

Esposito A, Criscitiello C, Salè EO, Curigliano G.

Expert Rev Clin Pharmacol. 2014 Sep;7(5):605-11. doi: 10.1586/17512433.2014.945429. Epub 2014 Aug 1. Review.

PMID:
25080998
Items per page

Supplemental Content

Write to the Help Desk